论文部分内容阅读
目的观察替罗非班(ⅡbⅢ/a受体拮抗剂)在急性冠脉综合征(ACS)患者的临床应用及安全性。方法急性冠脉综合征患者58例,随机分为两组,常规治疗组和常规治疗组+替罗非班组。观察15 d两组复合事件发生率(死亡、再梗死、心绞痛)和出血事件。结果替罗非班组心脏复合终点事件发生率明显低于常规治疗组,出血事件主要发生在牙龈出血及皮下出血,未发生颅内出血等事件。结论替罗非班在ACS的常规治疗基础上能进一步减少心肌缺血事件,安全、有效。
Objective To observe the clinical application and safety of tirofiban (Ⅱb Ⅲ / a receptor antagonist) in patients with acute coronary syndrome (ACS). Methods Fifty-eight patients with acute coronary syndrome were randomly divided into two groups: conventional treatment group and conventional treatment group plus tirofiban group. The incidence of composite events (death, reinfarction, angina) and bleeding events were observed on the 15th day. Results The incidence of cardiac composite end point in tirofiban group was significantly lower than that in routine treatment group. The bleeding events mainly occurred in gingival bleeding and subcutaneous hemorrhage without intracranial hemorrhage. Conclusion Tirofiban can further reduce myocardial ischemic events on the basis of routine treatment of ACS, which is safe and effective.